StockMacro
Company, fund or insider

Help

Menu

Odyssey Therapeutics

$16.96 -3.4% in 6 monthsMarket cap $815.2M

ODTX on XNAS, Health Care, Odyssey Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Institutional holders rose 26% last quarter to 72 while 7.0% of shares are sold short.

  • BadShare price down 11% in one month, to $16.96

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

Industry
Biological products, (no diagnostic substances) (Health Care)
Website
odysseytx.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $53.1M.
Quarter to 31 Mar 2025: revenue $1.9M, net income -$38.4MQuarter to 31 Mar 2025: revenue $1.9M, net income -$38.4MQuarter to 30 Jun 2025: revenue $959K, net income -$41.2MQuarter to 30 Jun 2025: revenue $959K, net income -$41.2MQuarter to 30 Sep 2025: revenue $99K, net income -$35.5MQuarter to 30 Sep 2025: revenue $99K, net income -$35.5MQuarter to 31 Mar 2026: revenue $0, net income -$38.3MQuarter to 31 Mar 2026: revenue $0, net income -$38.3MQuarter to 30 Jun 2026: revenue $0, net income -$52.8MQuarter to 30 Jun 2026: revenue $0, net income -$52.8MQuarter to 30 Sep 2026: revenue $0, net income -$53.1MQuarter to 30 Sep 2026: revenue $0, net income -$53.1M
31 Mar 2025RevenueNet incomeNet losstallest bar $53.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$53.1M
30 Jun 2026$0-$52.8M
31 Mar 2026$0-$38.3M
30 Sep 2025$99K-$35.5M
30 Jun 2025$959K-$41.2M
31 Mar 2025$1.9M-$38.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. – –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $326.0M $49.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $7.82
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Odyssey TherapeuticsODTX (this company) $815.2M––––
Prime MedicinePRME $791.6Mloss–––
MeiraGTxMGTX $779.9M10.01.9+1366%19.5%
Monte Rosa TherapeuticsGLUE $738.3Mloss10.5-61%-186%
Aura BiosciencesAURA $715.0Mloss–––
Solid BiosciencesSLDB $697.6Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+26%

72 13F filers vs 57

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

79%

37.9M shares held by 13F filers (30 Sep 2026) of 48.1M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

7.0%

3.3M shares sold short (30 Oct 2026) of 48.1M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

15.4

3.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.0%

3.3M shares sold short in the report before, 3.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

71%

71% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 68%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Price $16.96 on 20 Nov 2026, +3.3% over 12 months (12-month range $15.56 to $28.76)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $75.3M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $504K in the latest quarter, +950% on a year earlier.
Institutional holders (13F filers). 72 13F filers reported holding it in the latest 13F quarter, +26% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
12 May 2026Sharp changeClustered insider buying: clustered insider buying (5 independent filers, 5 filing(s) in 30 days, value_usd total 30.3M)
4 May 20268-K and other filingsRegistered new securities for sale (S-1)
17 Apr 20268-K and other filingsRegistered new securities for sale (S-1)
4 Dec 20258-K and other filingsPrivate placement of securities (Form D)
17 Jan 20258-K and other filingsRegistered new securities for sale (S-1)
15 Dec 20238-K and other filingsPrivate placement of securities (Form D)
27 Oct 20228-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 May 2026: $75.3M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Jul 2024: 1 published
Revenue per quarter
Quarter ended 31 Mar 2025: $1.9M; public on 18 Jun 2026
Quarter ended 30 Jun 2025: $959K; public on 7 Aug 2026
Quarter ended 30 Sep 2025: $99K; public on 5 Nov 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 18 Jun 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2025: $927K; public on 18 Jun 2026
Quarter ended 30 Jun 2025: $29K; public on 7 Aug 2026
Quarter ended 30 Sep 2025: $48K; public on 5 Nov 2026
Quarter ended 31 Mar 2026: $148K, -84% on a year earlier; public on 18 Jun 2026
Quarter ended 30 Jun 2026: $186K, +541% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $504K, +950% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
30 Jun 2026 report: 57; public on 14 Aug 2026
30 Sep 2026 report: 72; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F funds opening a position at 21 (30 Sep 2026), 63% below its normal reading of 57.
  • Insider net buying (open market): Insiders bought a net $75.3M in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months.
  • Revenue per quarter: Revenue $0 in the latest quarter, -100% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 8 insider trades

No trades in the last 90 days; the latest was filed 13 May 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 May 2026James G Coulter and 2 othersFormer 10% OwnerBuy1,388,889$18.00$25.0MForm 4
12 May 2026Dimension Capital II, L.P.DirectorBuy1,111,111$18.00$20.0MForm 4
11 May 2026Jason HaasChief Financial OfficerBuy1,000$20.00$20KForm 4
11 May 2026Shelley ChuDirectorBuy11,111$18.00$200KForm 4
11 May 2026Nan (ln) LiDirectorBuy1,111,111$18.00$20.0MForm 4
11 May 2026Jeffrey M LeidenDirectorBuy5,000$20.00$100KForm 4
11 May 2026Simeon George and 1 other10% ownerSell1,780$18.00$32KForm 4
11 May 2026Simeon George and 1 other10% ownerBuy555,555$18.00$10.0MForm 4

72 institutions reported shares at the end of Q3 2026, 79% of the shares outstanding; 21 opened a position, 8 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)6.2M13.0%$135.8M+1.1M+20%
Sr One Capital Management, LP3.8M7.89%$84.3MNo change
TPG GP A, LLC3.7M7.68%$82.0MNo change
Lightspeed Management Company, L.L.C.3.6M7.51%$80.2MNo change
Orbimed Advisors LLC3.0M6.24%$66.7MNo change
Sanofi2.0M4.14%$44.2M-1,718-0.1%
MPM Bioimpact LLC1.3M2.68%$28.6MNew+1.3M
Affinity Asset Advisors, LLC1.3M2.62%$28.0M+494K+64%
BlackRock, Inc.1.1M2.38%$25.4M+903K+375%
Deerfield Management Company, L.P.1.0M2.18%$23.2MNo change

Company events

All 8 company events

In 12 months: 2 share registrations, 1 private placement, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
11 May 2026Signed a major agreementSame filing: sold shares privately, changed its bylaws or fiscal year8-K
4 May 2026Registered new securities for sale (S-1)S-1/A
17 Apr 2026Registered new securities for sale (S-1)S-1
4 Dec 2025Private placement of securities (Form D)$214.0M sold of $214.0M offeredD
17 Jan 2025Registered new securities for sale (S-1)S-1
15 Dec 2023Private placement of securities (Form D)$97.1M sold of $106.0M offeredD
27 Oct 2022Private placement of securities (Form D)$168.0M sold of $174.9M offeredD
14 Oct 2021Private placement of securities (Form D)$91.6M soldD

The 5 newest of 110 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 14 May 2026Insiders record

    COULTER JAMES G (Former 10% Owner) and 2 other(s) bought 1,388,889 shares of ODTX ($25.0M) (dated 13 May 2026)

  2. 13 May 2026Insiders record

    Dimension Capital II, L.P. (director) bought 1,111,111 shares of ODTX ($20.0M) (dated 12 May 2026)

  3. 12 May 2026Insiders change

    had 5 insiders buy $30.3M of its shares on the open market within 30 days (5 filings).

    Who bought: Leiden Jeffrey M, Li Nan (LN), Chu Shelley, Haas Jason.

    See the evidence (5 source records)
    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $30.3M
    Window
    12 Apr 2026 to 12 May 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  4. 12 May 2026Insiders record

    Haas Jason (Chief Financial Officer) bought 1,000 shares of ODTX ($20,000) (dated 11 May 2026)

  5. 12 May 2026Insiders record

    Chu Shelley (director) bought 11,111 shares of ODTX ($199,998) (dated 11 May 2026)

  6. 12 May 2026Insiders record

    Li Nan (LN) (director) bought 1,111,111 shares of ODTX ($20.0M) (dated 11 May 2026)

  7. 12 May 2026Insiders record

    LEIDEN JEFFREY M (director) bought 5,000 shares of ODTX ($100,000) (dated 11 May 2026)

  8. 12 May 2026Insiders record

    George Simeon (ten percent owner) and 1 other(s) bought 555,555 shares of ODTX ($10.0M) (dated 11 May 2026)

  9. 4 May 2026Filings record

    Registered new securities for sale (S-1)

  10. 17 Apr 2026Filings record

    Registered new securities for sale (S-1)

  11. 4 Dec 2025Filings record

    Private placement of securities (Form D)

  12. 17 Jan 2025Filings record

    Registered new securities for sale (S-1)

  13. 15 Dec 2023Filings record

    Private placement of securities (Form D)

  14. 27 Oct 2022Filings record

    Private placement of securities (Form D)

  15. 14 Oct 2021Filings record

    Private placement of securities (Form D)

Not listed: 8 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001882782
Ticker
ODTX
Domain
odysseytx.com
Employer name
Odyssey Therapeutics Inc (1 unverified)
Fein
86-3384382 (1 unverified)
Hq location
MA|BOSTON|02210 (1 unverified)
Name
Odyssey Therapeutics, Inc.
  • DOL H-1B labor condition applications and PERM certifications12 data points2 Oct 2023 to 17 Nov 2025
  • SEC Form 13F institutional holdings18 data points30 Jun 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)14 records14 Oct 2021 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)81 data points31 Dec 2024 to 2 Nov 2026
  • SEC Form 4 insider transactions8 records, 12 data points11 May 2026 to 13 May 2026
  • FINRA short interest (twice monthly)35 data points15 May 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)274 data points8 May 2026 to 20 Nov 2026